Pharmacogenetics, the tailoring of drug treatment according to individual
genotype, has been widely proclaimed as a first step toward personalized medicine.
In this issue of THE JOURNAL, Chasman et al1 report
the association of 2 common polymorphisms in the 3-hydroxy-3-methylglutaryl-CoA
reductase (HMGCR) gene with reduced efficacy of pravastatin
therapy. In a survey of 148 single nucleotide polymorphisms in 10 genes involved
in lipid metabolism, carriers of 2 linked SNPs in the HMGCR gene showed significantly smaller reductions in levels of cholesterol,
triglycerides, and low-density lipoprotein cholesterol with treatment. Statins,
the most potent and widely used cholesterol-lowering drugs, function as competitive
inhibitors of HMGCR, the rate-limiting enzyme for cholesterol synthesis. This
study is the first to demonstrate the impact of genetic variation in the HMGCR
drug target for this popular class of drugs, justifying the need for further
study to validate and perhaps translate these findings into the clinical setting.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 24
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.